Tecentriq Data Builds As IMpower132 In NSCLC Meets PFS Co-Primary Endpoint

 
• By Sten Stovall
  
Xray
Roche's IMpower132 Tecentriq Combo Trial Is Positive In NSCLC • Source: Shutterstock

More from Clinical Trials

More from R&D